TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discharge Planning for Older Adults in the Emergency Department: Use of a Brief Phone Call After Discharge to Decrease Return Visits to the Emergency Department and Re-admissions to the Hospital
Brief Summary: The purpose of this study is to determine whether a phone call from a nurse within 1-3 days after discharge from the Emergency Department (ED) decreases return visits to the ED/ hospital admissions/ death (combined outcome) in patients age 65 and above. As secondary outcomes, time to follow up appointment with physician and economic impact of this intervention will be assessed.

Patients 65 years of age and older will be randomized following discharge from the ED into one of two groups. Group 1(Intervention) will receive a phone call collecting information about understanding of ED discharge instructions and guiding patient through the discharge instructions, and Group 2 (Placebo) will receive a follow up phone call for a satisfaction survey.

We hypothesize return visits to the ED and readmission to the hospital will decrease as a result of the nurse phone call intervention.


Options:
A: Arm Label: sPATH; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): sPATH
B: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
C: Arm Label: Satisfaction Survey; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo Comparator | Arm Label: ED Discharge and Medication Call; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ED Discharge & Medication Call | Intervention Type: BEHAVIORAL; Name: ED Discharge & Medication Call; Assigned to Arm(s): ED Discharge and Medication Call | Intervention Type: BEHAVIORAL; Name: Placebo Comparator; Assigned to Arm(s): Satisfaction Survey
D: Intervention Type: BEHAVIORAL; Name: Early hospital discharge facilitated by close nurse practitioner follow-up; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes in Obese, Subfertile Women
Brief Summary: This is a study to determine whether a low calorie diet using meal replacement shakes compared to current counseling about diet, followed by 3 cycles of clomiphene citrate (if needed) will result in: 1) improvements in ability to ovulate and achieve pregnancy either spontaneously or during 3 clomiphene citrate cycles 2) greater weight loss with reductions in waist and hip circumferences and improvements in hormones that are involved in allowing pregnancy to occur and hormones that are involved in metabolism, such as insulin and glucose (sugar) 3) improvements in other health conditions such as blood pressure, and emotional and physical well-being.

Women eligible to participate will be between the ages of 18-35 with a BMI (ratio of weight in kg divided by height in m2) of ≥ 35≤45 kg/m2 who are seeking help for anovulatory infertility including women with a diagnosis of polycystic ovarian syndrome (PCOS).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intensive Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Intensive Dietary Intervention; Assigned to Arm(s): Intensive Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: High dose Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Arm Label: Low dose Vitamin D; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): High dose Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): Low dose Vitamin D
C: Arm Label: PreLiFe-programme; Type: EXPERIMENTAL; Interventions: Behavioral: PreLiFe-programme, Behavioral: Attention Control Programme | Arm Label: Attention Control; Type: OTHER; Interventions: Behavioral: Attention Control Programme | Intervention Type: BEHAVIORAL; Name: PreLiFe-programme; Assigned to Arm(s): PreLiFe-programme | Intervention Type: BEHAVIORAL; Name: Attention Control Programme; Assigned to Arm(s): Attention Control, PreLiFe-programme
D: Arm Label: Control (Spa Certificate); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Mind/Body Program; Type: EXPERIMENTAL; Interventions: Behavioral: Mind/Body Program | Intervention Type: BEHAVIORAL; Name: Mind/Body Program; Assigned to Arm(s): Mind/Body Program | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control (Spa Certificate)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes in Obese, Subfertile Women
Brief Summary: This is a study to determine whether a low calorie diet using meal replacement shakes compared to current counseling about diet, followed by 3 cycles of clomiphene citrate (if needed) will result in: 1) improvements in ability to ovulate and achieve pregnancy either spontaneously or during 3 clomiphene citrate cycles 2) greater weight loss with reductions in waist and hip circumferences and improvements in hormones that are involved in allowing pregnancy to occur and hormones that are involved in metabolism, such as insulin and glucose (sugar) 3) improvements in other health conditions such as blood pressure, and emotional and physical well-being.

Women eligible to participate will be between the ages of 18-35 with a BMI (ratio of weight in kg divided by height in m2) of ≥ 35≤45 kg/m2 who are seeking help for anovulatory infertility including women with a diagnosis of polycystic ovarian syndrome (PCOS).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Arm Label: Intensive Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Intensive Dietary Intervention; Assigned to Arm(s): Intensive Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group
C: Arm Label: liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: metformin and liraglutide; Type: EXPERIMENTAL; Interventions: Drug: metformin and liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: metformin and liraglutide; Assigned to Arm(s): metformin and liraglutide
D: Arm Label: BMI > 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: BMI </= 32; Type: EXPERIMENTAL; Interventions: Drug: Metformin + Clomiphene, Drug: Metformin, Drug: Clomiphene | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BMI > 32 | Intervention Type: DRUG; Name: Metformin + Clomiphene; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): BMI </= 32 | Intervention Type: DRUG; Name: Clomiphene; Assigned to Arm(s): BMI </= 32

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Phone One Way Short Message Service (SMS) Versus SMS Dialogue for Women's and Child Health (Mobile WACh) in Kenya: A Randomized Control Trial
Brief Summary: With the increased prevalence of cellular phones, mobile technology provides an important tool to reach underserved populations in low to middle income countries. mHealth interventions offer promise to improve maternal child health throughout the reproductive health continuum if they contribute to increasing skilled birth attendance, family planning and exclusive breastfeeding. We propose a randomized clinical trial to determine effect of using mobile phones to deliver SMS (one-way) versus an interactive SMS dialogue (two-way) on uptake of reproductive and neonatal health services and maternal and infant outcomes


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (text); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Arm Label: Intervention Plus (text+quitline); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Intervention Type: BEHAVIORAL; Name: SmokefreeMOM Text; Assigned to Arm(s): Intervention (text), Intervention Plus (text+quitline)
B: Arm Label: Text Message; Type: EXPERIMENTAL; Interventions: Other: Text Message | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text Message
C: Arm Label: Two-way SMS dialogue; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS Dialogue | Arm Label: One-way SMS Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: One-way SMS Messaging | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS Dialogue; Assigned to Arm(s): Two-way SMS dialogue | Intervention Type: BEHAVIORAL; Name: One-way SMS Messaging; Assigned to Arm(s): One-way SMS Messaging
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Time-Restricted Feeding to Improve Glucose Tolerance and Vascular Condition
Brief Summary: The purpose of this pilot study is to find out what eating meals in a short time period early in the day (time-restricted feeding) versus eating meals spread out during the day (grazing) does to the body's ability to control blood sugar and to the health of its blood vessels.

The investigators hypothesize that time-restricted feeding will be more effective at improving glucose tolerance and vascular condition (inflammation and micro- and macro-vascular function) than grazing.


Options:
A: Arm Label: Time restricted feeding; Type: EXPERIMENTAL; Interventions: Other: Time restricted feeding | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Time restricted feeding; Assigned to Arm(s): Time restricted feeding
B: Arm Label: Alternate day fasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Alternate day fasting | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Alternate day fasting; Assigned to Arm(s): Alternate day fasting
C: Arm Label: Time-Restricted Feeding (early in the day eating); Type: EXPERIMENTAL; Interventions: Other: Time-Restricted Feeding | Arm Label: Grazing; Type: PLACEBO_COMPARATOR; Interventions: Other: Grazing | Intervention Type: OTHER; Name: Time-Restricted Feeding; Assigned to Arm(s): Time-Restricted Feeding (early in the day eating) | Intervention Type: OTHER; Name: Grazing; Assigned to Arm(s): Grazing
D: Arm Label: Normal Feeding; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Time Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): Time Restricted Feeding

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage
Brief Summary: The primary purpose of this study is to compare the efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2
B: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
C: Arm Label: Iron isomaltoside 1000 (Monofer®); Type: EXPERIMENTAL; Interventions: Drug: Iron isomaltoside 1000 | Arm Label: Standard medical Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard medical Care | Intervention Type: DRUG; Name: Iron isomaltoside 1000; Assigned to Arm(s): Iron isomaltoside 1000 (Monofer®) | Intervention Type: OTHER; Name: Standard medical Care; Assigned to Arm(s): Standard medical Care
D: Arm Label: VIT-45; Type: EXPERIMENTAL; Interventions: Drug: VIT-45 | Arm Label: Oral iron tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral iron tablets | Intervention Type: DRUG; Name: Oral iron tablets; Assigned to Arm(s): Oral iron tablets | Intervention Type: DRUG; Name: VIT-45; Assigned to Arm(s): VIT-45

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Brief Summary: The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain crises. SelG1 prevents various cells in the bloodstream from sticking together. By stopping these cell-cell interactions, SelG1 may prevent small blood vessels from becoming blocked and therefore reduce the occurrence and severity of pain crises. Other effects of SelG1 was evaluated, as well as the safety of the drug and how long it stayed in the blood stream.

Funding Source - FDA Office of Orphan Products Development (OOPD)


Options:
A: Arm Label: Moderate Dose Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea (Moderate Dose) | Arm Label: Low Dose Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea (Low Dose) | Intervention Type: DRUG; Name: Hydroxyurea (Moderate Dose); Assigned to Arm(s): Moderate Dose Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea (Low Dose); Assigned to Arm(s): Low Dose Hydroxyurea
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
C: Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: High-dose SelG1 (Selg1 5.0 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: SelG1 | Arm Label: Low-dose SelG1 (Selg1 2.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: SelG1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SelG1; Assigned to Arm(s): High-dose SelG1 (Selg1 5.0 mg/kg), Low-dose SelG1 (Selg1 2.5 mg/kg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age
Brief Summary: The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.


Options:
A: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin
B: Arm Label: dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age
Brief Summary: The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C